134 related articles for article (PubMed ID: 30680668)
1. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.
Sakurai M; Kikuchi T; Karigane D; Kasahara H; Matsuki E; Hashida R; Yamane Y; Abe R; Koda Y; Toyama T; Kato J; Shimizu T; Yokoyama Y; Suzuki S; Nakamura T; Okamoto S; Mori T
Int J Hematol; 2019 Mar; 109(3):292-298. PubMed ID: 30680668
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Cesini L; Carmosino I; Breccia M; De Benedittis D; Mohamed S; De Luca ML; Colafigli G; Molica M; Scalzulli E; Massaro F; Mariggiò E; Rizzo L; Loglisci MG; Scamuffa MC; Vozella F; Diverio D; Mancini M; Alimena G; Foà R; Latagliata R
Oncol Res Treat; 2019; 42(12):660-664. PubMed ID: 31593970
[TBL] [Abstract][Full Text] [Related]
3. Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients.
Singh AK; Vidyadhari A; Bhurani D; Agrawal N; Ahmed R; Sharma M
J Oncol Pharm Pract; 2023 Dec; 29(8):1928-1934. PubMed ID: 36862651
[TBL] [Abstract][Full Text] [Related]
4. Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.
Vidal-Petiot E; Rea D; Serrano F; Stehlé T; Gardin C; Rousselot P; Peraldi MN; Flamant M
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):169-74. PubMed ID: 26795084
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Cortes J; O'Brien S; Quintas A; Giles F; Shan J; Rios MB; Talpaz M; Kantarjian H
Cancer; 2004 Jun; 100(11):2396-402. PubMed ID: 15160343
[TBL] [Abstract][Full Text] [Related]
7. Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Ángeles-Velázquez JL; Hurtado-Monroy R; Vargas-Viveros P; Carrillo-Muñoz S; Candelaria-Hernández M
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S82-5. PubMed ID: 27521331
[TBL] [Abstract][Full Text] [Related]
8. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Kantarjian H; Talpaz M; O'Brien S; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Shan J; Rios MB; Champlin R; de Lima M; Cortes J
Cancer; 2005 May; 103(10):2099-108. PubMed ID: 15830345
[TBL] [Abstract][Full Text] [Related]
9. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
Lee SE; Choi SY; Song HY; Kim SH; Choi MY; Park JS; Kim HJ; Kim SH; Zang DY; Oh S; Kim H; Do YR; Kwak JY; Kim JA; Kim DY; Mun YC; Lee WS; Chang MH; Park J; Kwon JH; Kim DW
Haematologica; 2016 Jun; 101(6):717-23. PubMed ID: 26888022
[TBL] [Abstract][Full Text] [Related]
10. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
11. Hematologic, liver enzymes and electrolytes changes in chronic myeloid leukemia after Imatinib medication.
Moshfeghi K; Nazemizadeh N; Mehrzad V; Hajiannejad A; Esmaeili F; Mohammadbeigi A
Indian J Cancer; 2015; 52(3):305-7. PubMed ID: 26905120
[TBL] [Abstract][Full Text] [Related]
12. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
Ko PS; Yu YB; Liu YC; Wu YT; Hung MH; Gau JP; Liu CJ; Hsiao LT; Chen PM; Chiou TJ; Liu CY; Liu JH
Curr Med Res Opin; 2017 Oct; 33(10):1737-1744. PubMed ID: 28715941
[TBL] [Abstract][Full Text] [Related]
13. Higher hemoglobin level is associated with subtle declines in renal function and presence of cardiorenal risk factors in early CKD stages.
Oh SW; Baek SH; Kim YC; Goo HS; Chin HJ; Na KY; Chae DW; Kim S
Nephrol Dial Transplant; 2012 Jan; 27(1):267-75. PubMed ID: 21669882
[TBL] [Abstract][Full Text] [Related]
14. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
[TBL] [Abstract][Full Text] [Related]
16. Comment on "Effect of imatinib treatment on renal anemia in chronic myeloid leukemia patients".
Ansari R; Taghizadeh-Ghehi M
J Oncol Pharm Pract; 2023 Dec; 29(8):2057-2058. PubMed ID: 37743629
[No Abstract] [Full Text] [Related]
17. Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
Gómez-Sámano MÁ; Baquerizo-Burgos JE; Coronel MFC; Wong-Campoverde BD; Villanueva-Martinez F; Molina-Botello D; Avila-Rojo JA; Palacios-Báez L; Cuevas-Ramos D; Gomez-Perez FJ; Zentella-Dehesa A; Aguayo-González Á; Gulias-Herrero A
BMC Endocr Disord; 2018 Nov; 18(1):77. PubMed ID: 30390651
[TBL] [Abstract][Full Text] [Related]
18. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
19. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
20. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
